PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

BioStar Capital closes Fund V at $130.3m

BioStar Capital, a strategic healthtech venture capital firm focused on cardiovascular disease, orthopaedics, and robotics, has closed its fifth fund at $130.3m, more than the combined amount raised by the firm’s three previous funds.

Led by founder Louis Cannon, a cardiovascular physician, and orthopaedic surgeon Alan Davis, BioStar Capital’s Fund V portfolio already includes several medical device companies, including: Amplitude Vascular Systems (AVS), developing a groundbreaking intravascular lithotripsy device for treating heavily calcified arteries; Medical Microinstruments (MMI), the developer of a robotic device that permits doctors to operate at microsurgical levels for precision reconstruction of small blood vessels, nerves and lymphatics; and REVA Medical, which has developed the MOTIV Bioresorbable Scaffold that is designed to treat below-the-knee peripheral artery disease.

BioStar expects to invest in eight to 10 additional companies over the next five years.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured